Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Bullboard Posts
Post by snuff69on Mar 04, 2019 11:47pm
324 Views
Post# 29441766

George’s letter he’s even very excited

George’s letter he’s even very excited Here’s a copy of George’s email , this is the start of something great 
Dear Friend;

I know you will rejoice with me that the children and adults in China can now receive an accurate heart exam.

I can hear you saying: “It has been a long time coming”.  As usual, here is some background to go along with the attached NR in English and Mandarin.

1.    We ventured into China in 2013 with a false start with a large corporation as a distributor and they immediately underwent a restructuring and refused to move forward.
2.    In 2014, we got involved with Yutian and then assigned them the rights to establish a JV to manufacture, market, distribute and sell the existing VMS in China, which at the time was for right ventricle only.
3.    Fast forward 5 years and Yutian has finally gotten through the Chinese FDA for this first device.  It is actually a bit of a hi-bred as it uses the RV software and the newer VMS+ hardware.  It does not do 4 chambers and still uses the old tracking system.
4.    Obviously, they will go forward to get the full VMS+ (4 chambers and new hardware) approved but first they will establish the market with the RV-only system.
5.    Yutian has built a 40,000 sq. ft manufacturing facility Ma’amshan and produced 10 VMS+ machines.  The facility has GMP certification so the VMS+ are built to western standards.  The machines have also been verified to meet ISO60601 specifications (Chinese version of the international standard) for use in hospitals.  the factory is ready produced hundreds of VMS+ machines per year.
6.    The market in China is huge and the group is well connected to distribution channels that will rapidly roll out the VMS in the 2,500 tier 1 hospitals in China and then the other 30,000+ hospitals.  They have sales targets to maintain their rights and I know they will be working hard to meet them as they have spent so much time and money getting this far.  I am glad Ventripoint did not try to do this myself as we would have never had the patience and money to do it.
7.    Heart disease is a much bigger problem in China then in North America and the Chinese government is trying to get a handle on it as the 23%of hospital admissions are for cardiac dysfunction and this is the major reason they keep building more hospitals and expanding the healthcare service.  Like the rest of the world, their population is aging and so the number of elderly people with heart problems is increasing quickly.
8.    They actually use cardiac ultrasound as a screening tool to find people with heart problems early.  I saw this first hand when I visited a major provincial hospital.   People were lined up out the door and down the street to have an echocardiogram done.
9.    This was a major milestone in our original agreement to assign the rights for China to Yutian in exchange for investments in Ventripoint, service fees and equity in Yutian.  There are still some steps left to make this all happen and we will get them done as soon as possible.The Chinese do not like to tell much about financial arrangements due to competitive concerns, so we will give out what we can.  I can say that if only a fraction of what can happen in China happens we will do very well from it and it might even outshine the business in the western world given the overwhelming need.

Thanks for your continued support,

Regards,

George Adams, PhD, ICD.D
CEO
Ventripoint Diagnostics Ltd..
Cell: 519-803-6937
TSXV: VPT

Bullboard Posts